Regeneron eylea patent expiration?

See the DrugPatentWatch profile for eylea

When Does Exclusivity Expire for Eylea?

Regeneron Pharmaceuticals holds several patents for Eylea (aflibercept), a treatment for age-related macular degeneration (AMD). The company filed for these patents between 2009 and 2014, and they have varying expiration dates [1].

Patent Expiration Timeline

The US Patent and Trademark Office (USPTO) lists the following patents for Eylea:

- US Patent 9,231,661, which covers the method of use of aflibercept for treating neovascular (wet) age-related macular degeneration, expires on February 22, 2028 [2].
- US Patent 10,115,655, which covers a method of using aflibercept for treating choroidal neovascularization, expires on January 16, 2033 [3].

Biosimilars and Generic Competition

Regeneron has faced regulatory challenges to maintain exclusivity for Eylea. The loss of exclusivity could lead to competition from biosimilars and generic versions of the medicine [4].

Competitive Landscape and Pricing

Once Eylea's patent expires, biosimilars or generics could enter the market, potentially reducing prices and increasing competition. The development of these alternatives may be subject to various clinical trials and regulatory approvals before they can be marketed [5].

Sources:

[1] DrugPatentWatch.com
[2] US Patent and Trademark Office (USPTO)
[3] US Patent and Trademark Office (USPTO)
[4] Regeneron Pharmaceuticals
[5] StatNews